Overactive BladderNCT02086058
Gene Expression in the Overactive Bladder in Children
An observational study of Overactive Bladder and Children, run by University of Aarhus at 1 site in Denmark.
Trial summary
The aim of this study (the hypothesis) is to identify differences in the gene expression profile in the bladder muscle and hereby gain greater knowledge about the muscular mechanisms that cause overactive bladder and daytime urinary incontinence in children older than 5 years. Read more about this study
- Who is it for?
- Ages 5 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Overactive Bladder, Children
- How many people
- 46 participants
- Where
- 1 siteDenmark
- Study dates
- Nov 2013to Nov 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 80 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: We will include 3 groups of patients Group 1: children with an overactive bladder and daytime urinary incontinence Group 2: Children and adults with a neurogenic bladder Group 3: children and adults who have a healthy bladder
Who may be able to join
- Group 1: Group 1 (non-neurogenic bladder/overactive bladder):
- age 5-14 years of age
- patients must have filled out 48-hour bladder diaries
- a minimum of 4 micturitions per day (assessed from the bladder diaries)
- functional daytime urinary incontinence
- overactive bladder as defined by urgency
Show all 24Show fewer
- no signs of neurogenic bladder dysfunction on invasive urodynamics
- a non-remarkable clinical examination
- normal BMI (between 3-97 percentile)
- informed oral and written consent from the child and both parents/legal guardian. In the informed consent the parents /legal guardian have given permission to the authorities (The Danish Ethical Committee), so that they may get information about the child during monitoring and quality inspection visits.
- no effect of prior treatment of at least 6 months urotherapy
- no effect of prior treatment of at least 3 months of anticholinergic treatment
- planned to undergo a cystoscopy under anesthesia
- Group 2:
- 5-14 years of age or >18 years old
- diagnosed with a neurogenic bladder (i.e. caused by myelomeningocele)
- informed oral and written consent from the child and both parents/legal guardian. In the informed consent the parents /legal guardian have given permission to the authorities (The Danish Ethical Committee), so that they may get information about the child during monitoring and quality inspection visits.
- planned to undergo a cystoscopy under anesthesia
- Group 3:
- age 5-14 years of age or >18 years old
- a non-remarkable clinical examination
- a normal voiding pattern
- a minimum of 3 micturitions per day
- planned to undergo a cystoscopy under anesthesia
Who cannot join
- Group 1:
- Neurological and/or anatomical abnormalities in the lower urinary tract
- a medical history, clinical or biochemical tests that indicate that the child suffers from any type of disease (such as acute urinary infection or diabetes) or condition (such as pregnancy) influencing the child´s possibility of participating in the study, or that may effect the study parameters that are under examination.
- ongoing fecal problems such as fecal incontinence or constipation
- prior surgery involving the bladder
- ongoing urinary tract infections
Show all 18Show fewer
- ongoing treatment with any type of medicine that may effect the study parameters that are under examination
- Group 2:
- a medical history, clinical or biochemical tests that indicate that the child suffers from any type of diseases (such as diabetes) or conditions (such as pregnancy) influencing the child´s possibility of participating in the study, or that may affect the study parameters that are under examination.
- ongoing treatment with any type of medicine that may affect the study parameters that are under examination
- Group 3:
- Neurological and/or anatomical abnormalities in the lower urinary tract
- urinary incontinence and an overactive bladder with urinary incontinence
- a medical history, clinical or biochemical tests that indicate that the patient suffers from any type of disease (such as acute urinary tract infection or diabetes) or condition (such as pregnancy) influencing the patient´s possibility of participating in the study, or that may effect the study parameters that are under examination.
- any type of bladder disease or any disease secondary affecting the bladder
- prior bladder surgery
- ongoing urinary tract infection
- ongoing treatment with any type of medicine that may effect the study parameters that are under examination.
Trial locations and contacts
1 site in 1 country.
Denmark1 site, 1 recruiting
- Recruiting
Center for child incontinence, Aarhus University hospital
Aarhus, Aarhus N, 8200
About this study
Official title: Gene Expression in the Bladder in Children With an Overactive Bladder and Daytime Urinary Incontinence
The aim of this study (the hypothesis) is to identify differences in the gene expression profile in the bladder muscle and hereby gain greater knowledge about the muscular mechanisms that cause overactive bladder and daytime urinary incontinence in children older than 5 years. A secondary aim is to examine how this gene expression profile differs from children with a neurogenic overactive bladder and how the gene expression profile changes from childhood till adulthood. Such new knowledge will result in a more precisely targeted and hence effective treatment of overactive bladder.
The results will be obtained by retrieving bladder biopsies from children and adults suffering from an overactive bladder or a neurogenic bladder. These biopsies will undergo molecular analysis and the investigators will compare them with biopises from bladder healthy adults and children.
- Conditions
- Overactive Bladder, Children
- Keywords
- overactive bladder, daytime urinary incontinence, children, gene expression
- Medical subject headings
- Urinary Bladder, Overactive, Diurnal Enuresis
What is being measured
The primary outcome is the main question the study is designed to answer.
Up- and down regulation of genes expressed in the bladder
We will evaluate the gene expression (which genes are up- and/or down regulated) in the bladder in healthy children compared to children suffering from an overactive bladder. This gene expression will then be compared to the gene expression in bladder tissue from adults, to evaluate what happens in the bladder from childhood to adulthood.
Measured: collection of bladder material and analysis will take approximately 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2014 (estimated)
- Study startNov 2013
- Primary completionSep 2016 (estimated)
- Study completionNov 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overactive BladderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 46 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Ghent
- Responsible party
- Sponsor
- Investigators
- Luise Borch, M.D, Principal investigator, University of Aarhus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02086058
- Sponsor's protocol ID
- GeneOAB
- Status last verified
- Dec 2015
- First submitted
- 6 Mar 2014
- Last updated
- 18 Dec 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Gene Expression in the Bladder in Children With an Overactive Bladder and Daytime Urinary Incontinence
- ClinicalTrials.gov ID
- NCT02086058
- Acronym / sponsor ID
- GeneOAB
- Conditions
- Overactive Bladder, Children
- Keywords
- overactive bladder, daytime urinary incontinence, children, gene expression
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 46 participants (estimated)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Collaborators
- University Hospital, Ghent
- Study start
- Nov 2013
- Primary completion
- Sep 2016 (estimated)
- Study completion
- Nov 2016 (estimated)
- First posted
- 13 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study (the hypothesis) is to identify differences in the gene expression profile in the bladder muscle and hereby gain greater knowledge about the muscular mechanisms that cause overactive bladder and daytime urinary incontinence in children older than 5 years. A secondary aim is to examine how this gene expression profile differs from children with a neurogenic overactive bladder and how the gene expression profile changes from childhood till adulthood. Such new knowledge will result in a more precisely targeted and hence effective treatment of overactive bladder.
The results will be obtained by retrieving bladder biopsies from children and adults suffering from an overactive bladder or a neurogenic bladder. These biopsies will undergo molecular analysis and the investigators will compare them with biopises from bladder healthy adults and children.
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- 5 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- We will include 3 groups of patients Group 1: children with an overactive bladder and daytime urinary incontinence Group 2: Children and adults with a neurogenic bladder Group 3: children and adults who have a healthy bladder
Key inclusion criteria (24 listed)
- age 5-14 years of age
- patients must have filled out 48-hour bladder diaries
- a minimum of 4 micturitions per day (assessed from the bladder diaries)
- functional daytime urinary incontinence
- overactive bladder as defined by urgency
Key exclusion criteria (18 listed)
- Neurological and/or anatomical abnormalities in the lower urinary tract
- a medical history, clinical or biochemical tests that indicate that the child suffers from any type of disease (such as acute urinary infection or diabetes) or condition (such as pregnancy) influencing the child´s possibility of participating in the study, or that may effect the study parameters that are under examination.
- ongoing fecal problems such as fecal incontinence or constipation
- prior surgery involving the bladder
- ongoing urinary tract infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Up- and down regulation of genes expressed in the bladder
Time frame: collection of bladder material and analysis will take approximately 2 years
We will evaluate the gene expression (which genes are up- and/or down regulated) in the bladder in healthy children compared to children suffering from an overactive bladder. This gene expression will then be compared to the gene expression in bladder tissue from adults, to evaluate what happens in the bladder from childhood to adulthood.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2015.
Related trials for Overactive Bladder
Not yet recruitingPhase 4
Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
Overactive Bladder, Parkinson Disease
Recruiting
Ambulatory Long Length URodynamics Evaluation
Urology, Urinary Bladder, Overactive
Active, not recruiting
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
Overactive Bladder (OAB), Urinary Urgency
RecruitingObservational study
Tensi+ European Post-Market Clinical Follow-Up
Overactive Bladder
Not yet recruiting
Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke
Stroke, Neurogenic Overactive Bladder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luise Borch, M.D principal investigator
University of Aarhus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Overactive Bladder and Children, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 24 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Luise Borch, M.D (+45 22 92 55 02, luise.borch@ki.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Up- and down regulation of genes expressed in the bladder (time frame: collection of bladder material and analysis will take approximately 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2015.